देश: आयरलैंड
भाषा: अंग्रेज़ी
स्रोत: HPRA (Health Products Regulatory Authority)
Gabapentin
Aurobindo Pharma (Malta) Limited
N03AX12
Gabapentin
Capsule, hard
gabapentin
2022-10-21
PACKAGE LEAFLET: INFORMATION FOR THE USER GABAPENTIN AURO 100 MG HARD CAPSULES GABAPENTIN AURO 300 MG HARD CAPSULES GABAPENTIN AURO 400 MG HARD CAPSULES READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET? 1. What Gabapentin Auro is and what it is used for 2. What you need to know before you take Gabapentin Auro 3. How to take Gabapentin Auro 4. Possible side effects 5. How to store Gabapentin Auro 6. Contents of the pack and other information 1. WHAT GABAPENTIN AURO IS AND WHAT IT IS USED FOR Gabapentin Auro belongs to a group of medicines used to treat epilepsy and peripheral neuropathic pain (long lasting pain caused by damage to the nerves). The active substance in Gabapentin Auro is Gabapentin. Gabapentin Auro is used to treat Various forms of epilepsy (seizures that are initially limited to certain parts of the brain, whether the seizure spreads to other parts of the brain or not). The doctor treating you or your child 6 years of age and older will prescribe Gabapentin Auro to help treat epilepsy when the current treatment is not fully controlling the condition. You or your child 6 years of age and older should take Gabapentin Auro in addition to the current treatment unless told otherwise. Gabapentin Auro can also be used on its own to treat adults and children over 12 years of age. Peripheral neuropathic pain (long lasting pain caused by damage to the nerves). A variety of different diseases can cause peripheral neuropathic pain (primarily occurring in the legs and/or arms), such as diabetes पूरा दस्तावेज़ पढ़ें
Health Products Regulatory Authority 13 December 2023 CRN00DZ4R Page 1 of 12 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Gabapentin Auro100 mg hard capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 100 mg hard capsule contains 100 mg of gabapentin. Each 300 mg hard capsule contains 300 mg of gabapentin. Each 400 mg hard capsule contains 400 mg of gabapentin. For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Hard capsule White / White size '3' hard gelatin capsules imprinted with 'D' on white cap and '02' on white body with black edible ink, filled with white to off-white crystalline powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Epilepsy Gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and children aged 6 years and above (see section 5.1). Gabapentin is indicated as monotherapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents aged 12 years and above. Treatment of peripheral neuropathic pain Gabapentin is indicated for the treatment of peripheral neuropathic pain such as painful diabetic neuropathy and post-herpetic neuralgia in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology For all indications a titration scheme for the initiation of therapy is described in Table 1, which is recommended for adults and adolescents aged 12 years and above. Dosing instructions for children under 12 years of age are provided under a separate sub-heading later in this section. TABLE 1 DOSING CHART – INITIAL TITRATION DAY 1 DAY 2 DAY 3 300 mg once a day 300 mg two times a day 300 mg three times a day Discontinuation of gabapentin In accordance with current clinical practice, if gabapentin has to be discontinued it is recommended this should be done gradually over a minimum of 1 week independent of the indication. Epilepsy Health Products Regulatory Authority 13 December 2023 CRN00DZ4R Page 2 of 12 Epileps पूरा दस्तावेज़ पढ़ें